

# Epidemiology and the physiopathological link between depression and cardiovascular disease



Carmine Pizzi \*, Luigi Santarella, Raffaele Bugiardini

Department of Specialised, Experimental and Diagnostic Medicine, University of Bologna, Italy

## ARTICLE INFO

### Article history:

Received 6 October 2014

Accepted 20 October 2014

Available online 30 October 2014

### Keywords:

Depression disorders

Cardiovascular diseases

Patho-physiological mechanisms

## ABSTRACT

In the future, cardiovascular disease, together with depression, will be one of the leading causes of global disease in the Western World. It is well known that depression is independently associated with a poor prognosis in patients with ischemic heart disease.

Epidemiological studies suggest that in patients with coronary artery disease, depression symptoms identify patients with higher risk of adverse cardiovascular outcomes, other studies maintain that depression symptoms might influence the progression of coronary and peripheral atherosclerosis.

The defined pathophysiological pathways which link depression and cardiovascular outcomes are not well recognized although various mechanisms have been proposed to explain this association. Beyond traditional cardiovascular risk factors, autonomic nervous system, low grade of inflammation, platelet function, abnormal function of the hypothalamic–pituitary–adrenal axis and genetic factors can adversely impact the endothelium and arterial walls. Consequently, these mechanisms might be crucial factors in promoting and accelerating atherosclerosis and its complications due to plaque rupture and thrombosis. For these reasons, depression symptoms should be considered as a new cardiac risk factor in the general population and in patients with coronary artery disease.

© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

“For some time, I do not know why, I lost all my mirth: I neglect my exercises ...”

As William Shakespeare described a depressed Hamlet, in the same fashion we research the core aspects of depression: depressed mood, loss of interest and pleasure, and fatigue, all apparently belong to the purely psycho-social sphere, the correlations with the alteration of homeostasis and man/environment allostasis and their influence on the development of ischemic heart disease.

Scientific literature has abundantly shown how a percentage between 14% and 47% of patients with ischemic heart disease suffer from depressive symptoms, while the prevalence in the general population ranges from 4 to 7% [1], these data, however, do not fully explain the possible *consecutio temporum* between depression and coronary artery disease.

However, the latest scientific findings, which are crucial to the understanding of this etiological hypothesis, show how depression had been developing for a long time in many patients, and much earlier

than the appearance of their acute coronary syndromes, so as to play a negative prognostic role in the cardiac disease itself [2,3] (Fig. 1).

## 1. Pathophysiology of depression and cardiovascular disease

Various pathophysiological processes have been suggested to link the depressive syndrome to an accelerated atherogenesis, that ultimately results in acute coronary syndromes. In addition to an unhealthy lifestyle, several biological pathways may be involved that include dysregulation of the hypothalamic–pituitary–adrenal, abnormal autonomic tone, modifications in platelet function, systemic immune activation and endothelial dysfunction (Table 1).

### 1.1. Dysfunction of the autonomic nervous system


Depression is implicated in the dysregulation of the autonomic nervous system which in turn is implicated in the development of ischemic heart disease.

In particular, from a clinical point of view, hyperactivity of the sympathetic nervous system is associated with arterial hypertension, a decreased heart rate variability, a decreased vagal tone and an increase in the recovery time after stress, all factors related to increased cardiovascular mortality.

There is a directly proportional association between increased sympathetic activity and the severity of depression.

\* Corresponding author at: FESC, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (Padiglione 11), Università di Bologna, Via Giuseppe Massarenti 9, 40138 Bologna, Italy. Tel.: +39 051 6364911; fax: +39 051 392486.

E-mail address: [carmine.pizzi@unibo.it](mailto:carmine.pizzi@unibo.it) (C. Pizzi).



**Fig. 1.** Relative risk of traditional cardiovascular risk factors observed in the Framingham studies and relative danger of new cardiovascular risk factors from the data of the meta-analysis Traditional Cardiovascular Risk Factors.

The presence of depression in patients with ischemic heart disease determines a greater alteration in the sympatho-vagal balance compared with patients with only ischemic heart disease, suggesting that the effects of depression and ischemic heart disease are combined with the variability of the heartbeat [4].

### 1.2. Inflammation

Inflammatory cytokines play a key role in the genesis and evolution of atherosclerosis, unstable angina, acute myocardial infarction, ischemic heart disease and pathogenesis of chronic ischemic heart disease. Depression has been linked to increased levels of inflammatory cytokines (C-reactive protein, interleukin-1 and Interleukin-6) [5,6]. This association has been documented in depressed patients with or without cardiovascular disease. The presence of inflammation in depressed patients predicts future cardiac events. However, it seems that inflammation plays a minor role in mediating the effects of depression on cardiovascular disease.

In fact, it has been proven that depression heralds cardiovascular mortality in healthy subjects or with ischemic heart disease; but this association was circa 20% lower if the values of inflammatory cytokines were added to the multivariate analysis [7].

A recent study provides further evidence as to how depression is associated with an increase in cardiovascular mortality by assuming the value of the most significant prognostic factor with respect to the levels of C-reactive protein in patients with stable coronary artery disease [8]. Several authors [9,10] have shown that depression is

significantly associated with the metabolic syndrome, another risk factor for ischemic heart disease; inflammation and metabolic syndrome, may play a synergistic role in determining a higher incidence of coronary events through inflammatory cytokines.

### 1.3. Endothelial dysfunction

Endothelial dysfunction is involved in the altered control of vascular tone, proliferation of smooth vascular muscle cells, increased platelet aggregation, altered adhesive capacity of monocytes and leukocytes, decrease in the release of anti-inflammatory factors and decreased availability of nitric oxide.

All these factors account for the involvement of endothelial dysfunction in the clinical manifestations of atherosclerosis. Depression has been associated with impaired endothelial function in healthy subjects as well as in subjects with atherosclerosis, and in patients with ischemic heart disease. To confirm this correlation we have shown that treatment of depression with selective inhibitors of the serotonin re-uptake inhibitors (SSRIs) improves endothelial function in patients with ischemic heart disease and depression, providing further evidence that endothelial dysfunction is altered in depressed patients with ischemic heart disease [11].

### 1.4. Activity and increased platelet aggregation

Dysfunction and platelet aggregation activity are important factors in the genesis and evolution of acute coronary syndromes, atherosclerosis and thrombosis.

Alterations in the aggregation capacity and activity of platelets in patients with a major depression diagnosis are, hypothetically, related to an increase in morbidity and a decrease in survival compared to the general population.

Serotonin, an endogenous substance mainly involved in mood regulation and implicated in the pathogenesis of depression, can play a key role in the pathogenesis of myocardial ischemia through increased platelet aggregation.

The catecholamines bind to the platelet receptor (Alfa-2a) inducing an increase in the interplasmatic concentration of calcium, which in turn causes the de-granulation of alpha and beta granules. The de-granulation of alpha granules causes an increase in adhesion proteins and pro-inflammatory cytokines while the beta granules release serotonin, which leads to platelet aggregation and vasoconstriction [12].

**Table 1**  
Pathoetiological correlations between depression and cardiovascular diseases.

<i>Pathophysiological mechanisms</i>
Autonomic nervous system alterations
Pro-inflammatory activation
Pro-coagulant factors activation
Endothelial dysfunction
Hypothalamic–pituitary–adrenal axis alterations
Genetic predisposition
<i>Behavioral mechanisms</i>
Smoking
Physical activity
Diet
Therapeutic adherence

### 1.5. Alterations of the hypothalamic–pituitary–adrenal axis

Depressed patients show an activation of the hypothalamic–pituitary–adrenal axis [13,14]. Confirming this, it has been observed that almost 50% of patients with depression had high plasma cortisol levels and that circa 50% of non-depressed patients did not respond to tests for suppression of desametazone [15,16].

The involvement of the hypothalamic–pituitary–adrenal axis dysregulation and its dysregulation exposes the depressed subject to a series of metabolic disorders such as obesity, hypercholesterolemia, hypertriglyceridemia, hypertension, glucose intolerance and inflammation, which are directly responsible for a correlation with cardiovascular disease.

### 1.6. Genetic predisposition

Among the possible causes that correlate depression with cardiovascular disease, genetic alterations cannot be overlooked; in fact, studies have been made on genetic polymorphisms that encode key elements of the autonomic nervous system, the hypothalamic–pituitary–adrenal axis, serotonin, for membrane transporters for serotonin and inflammation, elements that play a key role in depression and ischemic heart disease.

Numerous studies are still underway to investigate the penetrance of these polymorphisms.

### 1.7. Behavioral factors

Various behavioral factors are involved in the relationship between depression and heart disease.

Depressed patients are less likely to change lifestyle, including diet, ceasing to smoke, and physical activity.

In particular, there seems to be a special relationship between physical inactivity and depression: several scientific studies have shown that active people are less depressed than sedentary people and inactive people who become active are at lower risk of developing depression.

The failure of hygienic measures for the lives of these patients contributes to worsening the prognosis. Moreover, according to a recent meta-analysis, these patients are at double the risk of non-adherence to prescribed treatment [17–20] and to the abuse of alcohol and smoking.

Finally, several studies show that depression significantly correlates with diabetes and obesity, known coronary risk factors.

## 2. Treatment of depression in cardiac patients

### 2.1. Pharmacological intervention

Several pharmacological interventions have been studied in depressed patients with cardiovascular disease. The tricyclics (TCAs) increase levels of serotonin, dopamine and norepinephrine in the central nervous system. These drugs are effective for the treatment of depression but should not be used in cardiac patients, given their tendency to cause orthostatic hypotension, conduction abnormalities of the stimulus with the appearance of arrhythmias and sudden death. In fact, TCAs were associated with an increase in adverse cardiac events in both healthy depressed subjects as well as in depressed patients with cardiovascular disease [21].

SSRIs appear to be safe and effective in patients with acute coronary syndrome and with chronic ischemic heart disease. These drugs act by inhibiting the reuptake of serotonin and lead to increased levels of the neurotransmitter in the synapse. SSRIs are safe in depressed patients with acute coronary syndrome. A recent meta-analysis showed that patients with ischemic heart disease treated with SSRIs have a better prognosis than patients treated with placebo [22].

Little data is available on the efficacy and safety of antidepressants in the treatment of depressed patients with cardiovascular disease.

### 2.2. Psychotherapeutic intervention

Psychotherapy is useful to improve depression but its usefulness in improving prognosis in the depressed cardiac patient is still debatable.

## 3. Conclusions

Scientific evidence shows that depression is a risk factor for cardiovascular morbidity and mortality [23]. A more complete understanding of the mechanisms that mediate the link between depression and heart disease could help develop treatments that improve the prognosis in these patients. Despite the existence of effective and safe treatments for depression in cardiac patients, the depression remains unrecognized and under-treated in this subgroup of patients. Surely depressed cardiac patients should be managed by a team of experts, such as cardiologist, psychiatrist, psychologist and family physician along with the family atmosphere. Only through this system can suitable programs be developed for the selection and treatment of depressed cardiac patients.

### Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

### References

- [1] van Melle JP, de Jong P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. *Psychosom Med* 2004;66:814–22.
- [2] Nicholson A, Kuper H, Hemingway H. Depression as an aetiological and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. *Eur Heart J* 2006;27:2763–74.
- [3] Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. *Biol Psychiatry* 2003;54:227–40.
- [4] Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. *Circulation* 2001;104:2024–8.
- [5] Kop WJ. The integration of cardiovascular behavioral medicine and psychoneuroimmunology: new developments based on converging research fields. *Brain Behav Immun* Aug 2003;17(4):233.
- [6] Kop WJ, Gottdiener JS, Tangen CM. Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia. *Am J Cardiol* Feb 15 2002;89(4):419–24.
- [7] Pizzi C, Manzoli L, Mancini S, Bedetti G, Fontana F, Costa GM. Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors. *Atherosclerosis* 2010;212:292–8.
- [8] Rallidis LS, Varounis C, Sourides V, et al. Mild depression versus C-reactive protein as a predictor of cardiovascular death: a three year follow-up of patients with stable coronary artery disease. *Curr Med Res Opin* Jul 2011;27(7):1407–13.
- [9] Ahlberg AC, Ljung T, Rosmond R, et al. Depression and anxiety symptoms in relation to anthropometry and metabolism in men. *Psychiatry Res* Oct 10 2002;112(2):101–10.
- [10] Licinio J, Wong ML. The interface of obesity and depression: risk factors for the metabolic syndrome. *Rev Bras Psiquiatr* Oct 2003;25(4):196–7 [Epub 2004 Jan 15].
- [11] Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. *Clin Pharmacol Ther* 2009;86:527–32.
- [12] Bruce EC, Musselman DL. Depression, alterations in platelet function, and ischemic heart disease. *Psychosom Med* 2005;67:S34–6.
- [13] Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. *Arch Gen Psychiatry* Jul 1998;55(7):580–92.
- [14] Parkes DG, Weisinger RS, May CN. Cardiovascular actions of CRH and urocortin: an update. *Peptides* May 2001;22(5):821–7.
- [15] Ehler U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus–pituitary–adrenal axis. *Biol Psychol* 2001;57(1–3):141–52.
- [16] Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress. *N Engl J Med* Aug 18 1988;319(7):413–20 [Review. Erratum in: *N Engl J Med* 1988 Nov 24; 319(21): 1428].
- [17] Wing RR, Phelan S, Tate D. The role of adherence in mediating the relationship between depression and health outcomes. *J Psychosom Res* 2002;53:877–81.
- [18] Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. *Eur Heart J* 2008;29:1110–7.

- [19] DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med* Jul 24 2000;160(14):2101–7.
- [20] Camacho TC, Roberts RE, Lazarus NB, Ga Kaplan, Cohen RD. Physical activity and depression: evidence from the Alameda County Study. *Am J Epidemiol* Jul 15 1991; 134(2):220–31.
- [21] Hamer M, David Batty G, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. *Eur Heart J* 2011;32:437–42.
- [22] Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. *Am J Cardiol* 2011;107:972–9.
- [23] Pizzi C, Costa GM, Santarella L, et al. Depression symptoms and the progression of carotid intima-media thickness: a 5-year follow-up study. *Atherosclerosis* 2014; 233:530–6.